Published on : May 17, 2016
ALBANY, New York, May 17, 2016: The report, titled “Global Parkinson’s Disease Market Report: 2016 Edition,” assesses the size, growth, and valuation of the market with the help of primary and secondary research methods, and various analytical tools. The growth of the market has been analyzed across the key regions. The report further profiles some of the prominent players operating in the global Parkinson’s disease market.
Parkinson’s disease refers to a progressive neurodegenerative disorder that leads to malfunction and eventually the death of vital nerve cells in the brain, better known as neurons. The disease primarily affects the neurons in a particular area of the brain, known as ‘substantia nigra’. Early signs of the disease are usually mild and go undetected. There has been no known cure for the disease so far and the treatment options include medications and surgery. The report points out the types of Parkinson’s disease, along with risk factors and treatment options. None of the current treatment options have been successful in fully restoring the brain function that produces dopamine. While both branded and generic drugs are available on the global Parkinson’s disease market, patent expiry of branded drugs is expected to boost the sales of generic drugs.
Click here to get more info with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=715352
The report points out that increasing life expectancy and rapidly growing geriatric population have boosted the growth of the global Parkinson’s disease market. Increasing exposure to toxins such as pesticides through food, air, and water is expected to lead to more Parkinson’s disease cases. The rise in healthcare expenditure, especially across the emerging economies, is expected to propel the growth of the global Parkinson’s disease market. However, the moderate growth of the market will be challenged by factors such as generic erosion, current treatment limitations, and higher risk of melanoma associated with the treatment of Parkinson’s disease. The overall market has been witnessing some positive trends including the introduction of stem cell therapy as a potential treatment option, drug development for late-stage Parkinson’s disease, and development of biologics.
The report studies the global Parkinson’s disease market across some of the key regions such as the U.S., Japan, and the European Union. The report studies the growth of each of these regional markets in terms of the number of patients, drug class, availability of branded and generic drugs, and valuation.
Describing the competitive landscape, the report profiles some of the key players in the global Parkinson’s disease market such as Adamas Pharmaceuticals Inc., Biotie Therapies Corp., Lundbeck, and Novartis. Insightful information about the key players such as business strategies, financial overview, and business overview has been included in the report. The market players are focusing on extensive research activities to develop innovative therapeutics and are conducting clinical trials.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org